Par Pharmaceutical Companies, Inc.™ develops, manufactures, markets and distributes high-quality pharmaceuticals through two divisions: Par Pharmaceutical , our generic drug division, and Strativa Pharmaceuticals , our proprietary products division. We combine the energy and innovation of a new venture with the fully integrated resources of a leading, diversified pharmaceutical company.

  • Founded as a generics products company in 1978. Today includes two divisions:
  • Employs more than 600 professionals in offices in Woodcliff Lake, New Jersey (Corporate Headquarters), Spring Valley, New Yor...More >>

Recent News

04/07/14Par Pharmaceutical Begins Shipment of Potassium Chloride Extended-Release Capsules
Woodcliff Lake, NJ, April 7, 2014 – Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for potassium chloride extended-release (ER) capsules, USP, in 600 mg (8 mEq K) and 750 mg (10 mEq K) strengths. Potassium chloride ER is indicated for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxications, in patients with hypokale... 
04/01/14Par Pharmaceutical Names Terrance J. Coughlin Chief Operating Officer
Woodcliff Lake, NJ, April 1, 2014 – Par Pharmaceutical Companies, Inc. today announced that Terrance J. Coughlin has been named chief operating officer. In this capacity, Mr. Coughlin will be responsible for Par’s global manufacturing activities, research and development efforts and will be instrumental in the new product selection process. Mr. Coughlin joins Par from Glenmark Generics, Inc. USA/Glenmark Generics Limited where he most recently served as president and chief exec... 
03/13/14Par Pharmaceutical Announces Fourth Quarter and Full Year 2013 Conference Call
Woodcliff Lake, N.J., March 13, 2014 – Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Thursday, March 20, 2014 at 10:00 a.m. EDT to review its results of operations for the fourth quarter and full year ended December 31, 2013.  Par is privately held and currently makes certain financial information available to the public in its filings with the Securities and Exchange Commission.  Par will file its financial statements for the yea... 
02/20/14Par Pharmaceutical Names Antonio R. Pera Chief Commercial Officer
Woodcliff Lake, NJ, February 20, 2014 – Par Pharmaceutical Companies, Inc. today announced that Antonio R. Pera has been named chief commercial officer.  Following its acquisition of JHP Pharmaceuticals, Mr. Pera has been chosen to lead Par’s newly-integrated sales and marketing organization.  In this capacity, he will be instrumental in managing Par’s relationships with its major trade partners.  Mr. Pera joins Par from JHP where he served as senior vic... 

Upcoming Events

There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.